Home
Company
Product
Regulation
China
Data
Exhibition
Interview
中文版
Home
Company
Product
Regulation
China
Data
Exhibition
Interview
中文版
Search

Heno Bio and 2Firsts to Hold Compliance Strategic Cooperation Launch Ceremony in Shenzhen

Events by 2FIRSTS
Jan.02.2025
Heno Bio and 2Firsts to Hold Compliance Strategic Cooperation Launch Ceremony in Shenzhen
2Firsts to hold global NGP compliance development seminar in Shenzhen on January 9th, 2025, featuring top industry leaders.

On January 9, 2025, 2Firsts will host the 2025 Global NGP Regulatory Development New Year Seminar in Shenzhen Qianhai.

 

At this seminar, leading global nicotine companies, Heno Biotech, and 2Firsts will jointly hold a ceremony to launch a compliance strategic partnership, aiming to work together to promote industry regulatory compliance and create a new future for the NGP industry.

 

Heno Bio and 2Firsts to Hold Compliance Strategic Cooperation Launch Ceremony in Shenzhen
Event Poster | Image source: 2Firsts

 

 

 

Also Read:
[1] 2Firsts Hosts Inaugural Open Day: Industry Review and 2025 NGP Trends Forecast
#Asia#China#Nicotine-free e-cigarettes#Major companies

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn

Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Glas, the FDA, and the Future of Flavored ENDS
Glas, the FDA, and the Future of Flavored ENDS
China Tobacco Regulation Shift：Policy Updates and Market Impact
China Tobacco Regulation Shift：Policy Updates and Market Impact
Special Report | New Patents Show China Tobacco Hubei Industrial Testing Gas-Releasing Nicotine Pouches
Special Report | New Patents Show China Tobacco Hubei Industrial Testing Gas-Releasing Nicotine Pouches
Newly published patent filings indicate that China Tobacco Hubei Industrial Co., Ltd., a subsidiary of China National Tobacco Corporation (CNTC), is exploring nicotine pouch technologies capable of releasing gas during oral use. The designs include carbon-dioxide microcapsules that burst in the mouth and effervescent systems that generate gas through chemical reactions with saliva, suggesting efforts to introduce new sensory dynamics into modern oral nicotine products.
News
Mar.04
Product | Claiming “U.S.-Made E-Liquid” and “80,000 Puffs,” VOOPOO Launches NAVI×Cyph 80K
Product | Claiming “U.S.-Made E-Liquid” and “80,000 Puffs,” VOOPOO Launches NAVI×Cyph 80K
VOOPOO’s website shows the company has introduced the NAVI×Cyph Kit 80K, an open-system, refillable vaping kit claimed to deliver up to 80,000 puffs. The device features a 1,500mAh battery with USB Type-C charging and comes in 12 flavors. A promotional image posted on VOOPOO’s official Instagram account includes the phrase “E-LIQUID BUILT IN THE USA.”
Feb.10 by 2FIRSTS.ai
Louisiana lawmaker pushes bill to ban vape product sales within 300 feet of schools
Louisiana lawmaker pushes bill to ban vape product sales within 300 feet of schools
A Louisiana lawmaker has introduced HB 302, which would prohibit businesses from selling vapor products within 300 feet of schools. The bill would measure the distance by a person walking on the sidewalk from the nearest point on school property to the nearest point of the business. It would also give the commissioner authority to modify how the distance is calculated, while maintaining the 300-foot limit.
Feb.26 by 2FIRSTS.ai
Florida AG announces largest illegal vape seizure in state history, 2,183 contraband devices seized
Florida AG announces largest illegal vape seizure in state history, 2,183 contraband devices seized
Florida’s attorney general announced a record-breaking statewide enforcement push against illegal vaping products, with four joint operations seizing 2,183 contraband vapes and additional nitrous oxide-related items. Regulators also reported removing thousands of noncompliant products from store shelves, while investigations remain ongoing.
Feb.09 by 2FIRSTS.ai
FDA Authorizes Glas Vape but Flavor Hopes Fall Short
FDA Authorizes Glas Vape but Flavor Hopes Fall Short
The FDA has added Glas products to its authorized electronic nicotine delivery systems (ENDS) list, granting Marketing Granted Orders (MGOs) to the Glas G DEVICE and a BLONDE TOBACCO pod. The decision expands the number of FDA-authorized ENDS products to 41, marking the first new authorization since Juul’s approvals in July 2025. However, widely anticipated non-tobacco flavored products were not approved.
Mar.13
Qnovia’s Heat-Free Inhalable Nicotine Replacement Therapy Posts Positive First-in-Human Data, Advances FDA and MHRA Filings as Funding Expands
Qnovia’s Heat-Free Inhalable Nicotine Replacement Therapy Posts Positive First-in-Human Data, Advances FDA and MHRA Filings as Funding Expands
U.S.-based medical startup Qnovia Inc. reported positive results from its first-in-human clinical trial of RespiRx, an inhalable nicotine replacement therapy (NRT) device designed to support smoking cessation.
Innovation
Feb.24
Related Topics
News
Related Read
Special Report | New Patents Show China Tobacco Hubei Industrial Testing Gas-Releasing Nicotine Pouches
Special Report | New Patents Show China Tobacco Hubei Industrial Testing Gas-Releasing Nicotine Pouches
Product | Claiming “U.S.-Made E-Liquid” and “80,000 Puffs,” VOOPOO Launches NAVI×Cyph 80K
Product | Claiming “U.S.-Made E-Liquid” and “80,000 Puffs,” VOOPOO Launches NAVI×Cyph 80K
2FIRSTS.ai
Louisiana lawmaker pushes bill to ban vape product sales within 300 feet of schools
Louisiana lawmaker pushes bill to ban vape product sales within 300 feet of schools
2FIRSTS.ai
Florida AG announces largest illegal vape seizure in state history, 2,183 contraband devices seized
Florida AG announces largest illegal vape seizure in state history, 2,183 contraband devices seized
2FIRSTS.ai
FDA Authorizes Glas Vape but Flavor Hopes Fall Short
FDA Authorizes Glas Vape but Flavor Hopes Fall Short
Qnovia’s Heat-Free Inhalable Nicotine Replacement Therapy Posts Positive First-in-Human Data, Advances FDA and MHRA Filings as Funding Expands
Qnovia’s Heat-Free Inhalable Nicotine Replacement Therapy Posts Positive First-in-Human Data, Advances FDA and MHRA Filings as Funding Expands
FOLLOW US ON SOCIAL MEDIA
Contact: info@2firsts.com
Stay up to date.
Submit your email to receive weekly newsletter on the most relevant news of the e-cigarette industry.
© 2026 2FIRSTS. All Right Reserved.
2FIRSTS is only accessible to industry practitioners, researchers, media and other professionals. Access by minors is prohibited.
This website provides services to users outside the Chinese mainland.
English
English
中文